June 29, 2020
Nordic digital therapeutics company SidekickHealth is partnering with pharma giant Pfizer to launch a digital therapeutics platform, in a deal thought to be worth more than $8 million.
The solution combines scientific expertise and digital technologies, giving patients a tool to help them maintain healthy lifestyles and improve their disease management and quality of life, while providing...
September 13, 2019
A new company out of London called Bold Health is combining digital tools and cognitive behavioral therapy with the aim of helping patients improve their gut health.
Earlier this month, the company launched its first product, Zemedy, an app targeted at treating irritable bowel syndrome symptoms through a combination of CBT, hypnotherapy exercises and stress management techniques.
“There is a...
August 6, 2019
Chicago-based metaMe Health, a startup focused on behavioral digital treatments gastrointestinal conditions, has raised $3.8 million in seed funding. LionBird Ventures led the round, which also saw contributions from Hemi Ventures and other unnamed backers.
WHAT THEY DO
The company’s lead product is Regulora, a treatment tackling the cognitive, behavioral and affective factors that can trigger...
May 31, 2018
Oshi Health, a digital startup focused on digestive health, has launched a mobile app specifically designed to help inflammatory bowel disease patients understand and manage their condition.
“What’s interesting about inflammatory bowel disease is that patients have very unique, individualized experiences,” Oshi CEO Daniel Weinstein told MobiHealthNews. “Some patients experience frequent,...
November 13, 2017
A software platform developed at Mount Sinai comprising of a mobile app for patients and a decision support dashboard for practitioners can improve inflammatory bowel disease (IBD) patients’ quality of care, according to clinical data recently presented at the Advances in Inflammatory Bowel Diseases Conference.
By implementing tools that allow care teams to monitor symptoms and more conveniently...
September 1, 2017
Cara, a Berlin-based startup building a medical app for digestive health (a space the company has boldly dubbed “poop tech”), has raised a $2 million seed round. Atlantic Labs led the round, and additional investments came from angel investors. The company does business as Cara, the name of its app, but is officially known as HiDoc.
“Digestive issues are still a taboo topic but we are now making...
May 8, 2017
Japanese health app maker Welby announced three new apps last month developed in partnership with pharma companies. Welby will add to its lineup three apps available only in Japan: an app for irritable bowel disease patients with Johnson & Johnson subsidiary Janssen; an app for pulmonary arterial hypertension (PAH) patients with Japanese pharma company Nippon Shinyaku, and an app for...
October 27, 2016
Litmus Health, a company helping pharma companies use wearable devices to improve the efficiency of Phase I and II drug trials, is coming out of public beta and announcing a trial with the University of Chicago testing the effects of activity, sleep, and diet on Inflammatory Bowel Disease (IBD) patients. The trial is funded via a grant from Takeda Pharmaeuticals.
"I see so many patients filling...
April 19, 2013
When Larry Smarr started exploring the biochemistry of his body, he turned to his microbiome to find answers. At TEDMED 2013, Smarr talked about the steps he took in the months before he discovered he had Crohn’s disease.
At first, Smarr used apps like Zeo and Fitbit to monitor his sleeping and exercise respectively. Eventually, Smarr delved deeper, turning his attention to blood work and stool...
September 18, 2012
The UCLA Center for Inflammatory Bowl Diseases just completed the pilot phase of a program that equips patients who have Crohn's disease and ulcerative colitis with iPads to help them track and monitor their conditions while staying in touch with their care team throughout the day as needed. Now that the pilot phase is over, UCLA is enrolling about 250 patients in the program.
"Using a tablet...